Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07465835RecruitingPhase 1
Testing ELA026 for T/NK cell cancers that returned or didn't respond
This trial tests an investigational drug called ELA026 for people with T-cell or NK-cell cancers that came back or didn't get better after prior treatment. The goal is to see if ELA026 can help shrink the cancer or slow its growth.
New Haven, ConnecticutAges 18 years+ - NCT07465757RecruitingPhase 2
Study of alisertib and paclitaxel for small cell lung cancer
This trial tests a combination of two drugs, alisertib and paclitaxel, for people with small cell lung cancer (SCLC) who have already had at least one type of platinum chemotherapy and an immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
AlicanteAges 18 years+ - NCT03327428Recruiting
Registry study for people with sickle cell disease
This study is a registry that collects information about people living with sickle cell disease. It may help researchers better understand sickle cell types in Germany, Austria, and Switzerland and support future research and care.
Heidelberg, Baden-WurttembergAges birth–100 years - NCT06752720RecruitingPhase 2
Stem cell therapy for chronic stroke patients
This trial tests whether a patient's own stem cells can be safely injected into the brain to help recovery after a stroke. It is for people who had an ischemic stroke 6 months to 5 years ago and still have moderate to severe symptoms.
Sapporo, HokkaidoAges 20–70 - NCT07464483Recruiting
Studying genetics in stem cell and CAR-T therapy patients
This trial analyzes genetic information from patients receiving a stem cell transplant or CAR-T therapy to better understand treatment outcomes. Participation may help researchers improve future therapies.
Bologna, BolognaAges Any age - NCT07465276RecruitingPhase 2
Two immunotherapies before surgery for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT07463508Recruiting
Bile acids as markers for testicular germ cell tumors
This study looks at whether levels of bile acids (substances made by your liver) can help doctors understand how testicular germ cell tumors grow and how they respond to treatment. It may help improve future care for people with this type of cancer.
Clermont-FerrandAges 18 years+ - NCT07471074Recruiting
Study of stem cells in Waldenström macroglobulinemia
This study looks at bone marrow stem cells in people with Waldenström macroglobulinemia (WM). It aims to understand how these cells work and may help improve future treatments for WM.
AmiensAges 18 years+ - NCT07471373Recruiting
Pesticides and infertility study in endometriosis
This study looks at how pesticides might affect fertility in women with endometriosis, focusing on stress markers and gut/genital bacteria. You will provide samples and answer questions so researchers can compare women with and without endometriosis.
SalouëlAges 18–43 - NCT07469709Recruiting
Cancer risk study using genetics and monitoring
This study looks at genetic and other factors in people with certain cancers to better understand personal cancer risks and improve monitoring. It may help find ways to detect changes earlier.
Candiolo, TurinAges 18 years+ - NCT07464951RecruitingPhase 1
CART123 cells with or without ruxolitinib for AML
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Philadelphia, PennsylvaniaAges birth–29 years - NCT05504278RecruitingPhase 1
Testing IBI351 with chemotherapy for KRAS G12C lung cancer
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
Jilin City, ChangchunAges 18–75 - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07460999Recruiting
Singing training after lung cancer surgery
This trial tests if singing training twice a week can help with ongoing symptoms like shortness of breath or fatigue 6 to 18 months after surgery for early-stage lung cancer.
CopenhagenAges 18 years+ - NCT07457281RecruitingPhase 1
A new drug combo for head and neck cancer before surgery
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
ChengduAges 18–70 - NCT07455032RecruitingPhase 1
Neoadjuvant therapy combo for head and neck cancer
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07460362RecruitingPhase 2
Glofitamab and lenalidomide for high-risk mantle cell lymphoma
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
Beijing, Beijing MunicipalityAges 18–80 - NCT07457125RecruitingPhase 1/Phase 2
Exosome therapy for mild to moderate Alzheimer's disease
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
BeijingAges 50 years+ - NCT06522919RecruitingPhase 2
Immunotherapy and chemotherapy for advanced colorectal cancer
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
Meldola, Forlì CesenaAges 18 years+ - NCT05451303Recruiting
Testing for oral and throat cancer risk with a mouth test
This trial studies how well an at-home or clinic mouth test (OralViome Cancer Testing System) can detect signs of risk for oral or throat cancer. You may benefit by getting cancer-risk testing if you are considered high risk, though results will guide whether further evaluation is needed.
New York, New YorkAges 18 years+ - NCT06174428Recruiting
Study of a new oral and throat cancer test
This study is testing a new, simple test that looks for signs of oral or throat cancer. If you have a suspicious spot or symptom, this test might help find out if it's cancer.
St Louis, MissouriAges 18 years+ - NCT05358262RecruitingPhase 2
Heated, humid air during stem cell transplant to reduce mouth injury
This Phase 2 study tests whether breathing in warm, very humid air through your nose during stem cell transplant (with high-dose melphalan) can reduce painful mouth or throat injury. It may help your comfort and recovery during and after treatment.
Edmonton, AlbertaAges 18 years+ - NCT07453095RecruitingPhase 2
Glofitamab for mantle cell lymphoma after CAR T-cell therapy
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
AlessandriaAges 18 years+ - NCT07448727Recruiting
Early PET scan for head and neck cancer on immunotherapy
This trial uses a special PET/CT scan early in treatment to see if first-line immunotherapy is working for people with recurrent or metastatic head and neck cancer. It aims to learn if early response can predict outcomes and help guide care.
Rome, ItalyAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.